Prognostic Influence of Spontaneous Tumor Rupture in Patients with Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies

Jiaxuan Xu

Zhejiang Chinese Medical University

Lihu Gu

Ningbo Huamei Hospital University of Chinese Academy of Sciences

Binbin Xu

Ningbo Huamei Hospital University of Chinese Academy of Sciences

Yuexiu Si

Zhejiang Chinese Medical University

Yujing He

Zhejiang Chinese Medical University

Ping Chen (✉ hello666813@126.com)

Ningbo Huamei Hospital University of Chinese Academy of Sciences

Research Article

Keywords: Hepatocellular carcinoma, Spontaneous tumor rupture, Hepatectomy, Prognosis, Meta-analysis

Posted Date: July 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-665806/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Frontiers in Surgery on November 16th, 2021. See the published version at <https://doi.org/10.3389/fsurg.2021.769233>.

Abstract

Background: This study aims to comprehensively analyze the influence of spontaneous tumor rupture on the prognosis of hepatocellular carcinoma patients following hepatic resection.

Methods: We systematically searched four online electronic databases, including PubMed, Embase, Web of Science, and Cochrane Library, for eligible studies published from inception to March 2021. The main endpoints were overall survival (OS) and disease-free survival (DFS).

Results: This meta-analysis included 21 observational articles with 57241 cases. The results revealed that spontaneous tumor rupture was associated with worse OS (hazard ratio (HR), 1.65; 95% confidence interval (CI), 1.33-2.05) and DFS (HR, 1.42; 95% CI, 1.12-1.80) in resectable hepatocellular carcinoma patients. This phenomenon was observed in most subgroups, which were classified by recorded survival time, age, country, alpha-fetoprotein (AFP) concentration, liver cirrhosis, and microvascular invasion. However, in subgroups of macrovascular invasion positive, spontaneous tumor rupture was not a risk factor for OS (HR, 1.55; 95% CI, 0.99-2.42) and DFS (HR, 1.23; 95% CI, 0.91-1.65) in hepatocellular carcinoma patients after hepatectomy. For macrovascular invasion negative, compared with non-ruptured hepatocellular carcinoma patients, ruptured hepatocellular carcinoma patients exhibited worse prognosis for OS (HR, 1.55; 95% CI, 0.99-2.42) and DFS (HR, 1.23; 95% CI, 0.91-1.65) following hepatectomy.

Conclusions: Spontaneous tumor rupture was a prognostic risk factor for hepatocellular carcinoma patients after hepatic resection. However, in macrovascular invasion patients, spontaneous tumor rupture was not a prognostic risk factor.

Background

Hepatocellular carcinoma (HCC), the sixth most prevalent primary neoplasm, was responsible for around 810000 deaths in 2015 worldwide [1, 2]. Spontaneous tumor rupture (STR) of HCC is a potentially fatal complication [3]. The mechanisms underlying STR remain unclear. Possible reasons include large tumor size, ischemic necrosis, and vascular compression caused by rapid tumor growth [4–6]. Although the overall incidence was relatively low (3%-26%), the mortality rates of ruptured HCC patients were extremely high (32%-75%) in reported literature [3, 7–11]. Nowadays, treating STR of HCC is challenging; the current interventions used clinically include conservative treatment, transcatheter arterial chemoembolization (TACE), and hepatic resection [12, 13]. Hepatectomy, including emergent and staged (after TACE achieving hemostasis) hepatectomy, provided a better long-term prognosis than palliative treatment in ruptured HCC patients with relatively well-preserved liver functions [13].

Traditionally, STR has recognized as a terminal event of HCC, as it could lead to various symptoms, such as hemorrhagic shock, intraperitoneal hemorrhage, and metastases, and most ruptured HCC patients had portal vein tumor thrombosis (PVTT), impaired liver function, and liver cirrhosis [14–17]. As a result, these advanced patients with STR were frequently unable to receive surgical treatment and were compelled to have non-surgical treatment, resulting in a worse long-term prognosis than advanced patients receiving the same therapy without STR [9, 12].

However, whether STR was a prognostic risk factor for HCC patients after hepatic resection remains unclear [18, 19]. Consequently, this meta-analysis aims to evaluate the long-term prognosis of patients with or without STR following hepatectomy and explore whether STR affects the prognosis of HCC patients after surgery.

Materials And Methods

Literature search strategy

This meta-analysis followed Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines [20]. Four online electronic databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched for published literature in English from inception to March 2021. The search strategies included: ("Hepatocellular Carcinoma" OR "Hepatoma" OR "Liver Cell Carcinomas" OR "HCC") AND ("Rupture"). Furthermore, potentially eligible studies were identified through a thorough inspection from reference lists of all retrieved papers.

Inclusion criteria

The inclusion criteria for this meta-analysis entailed: (1) Patients in experiment (ruptured HCC) and control (non-ruptured HCC) groups received hepatic resection, including emergent and staged hepatectomy. (2) The included literature is original and includes observational studies (OBSs). (3) The study evaluated the relationship between tumor rupture and prognosis. (4) The primary endpoints as overall survival (OS) or disease-free survival (DFS) were mentioned, and their hazard ratio (HR) and 95% confidence interval (CI) were obtainable or could be calculated.

Exclusion criteria

The exclusion criteria for this meta-analysis entailed: (1) The relationship between ruptured and non-ruptured HCC in the prognosis of patients has not been explored at the same time. (2) When the duplicate publications were reviewed, the higher-quality or most updated was included. (3) The intervention for patients was not surgery but like TACE alone and palliative chemotherapy. (4) Multiple hepatic metastases, distant organ metastasis, and lymph node metastases were found in patients. (5) The tumor rupture was not spontaneous, but it was caused by trauma.

Data extraction and quality evaluation

Based on pre-determined inclusion/exclusion criteria, two authors performed an independent review, extracting the following information carefully from each included study, including (1) study characteristics (author, country, and publication year), (2) patients' basic characteristics (age, gender, and number of

included patients), (3) hepatic features (serum AFP, virus status, and liver cirrhosis), (4) tumor features (tumor number, size, and invasion), (5) therapeutic effect (OS and DFS, and corresponding HR and 95% CI).

The quality of incorporated OBSs was assessed using Newcastle-Ottawa Scale (NOS) that encompassed three aspects (selection of patients, comparability of groups, and evaluation of outcomes). The cumulative scores of articles less than six were considered of low-quality [21].

Statistical analysis

The pooled HR and 95% CI for OS and DFS were calculated to estimate the relationship between tumor rupture and prognosis. Heterogeneity among included literature was assessed using I^2 statistic. For potential heterogeneity, random-effect models were employed for greater reliability. When the number of included articles in each analysis is ≥ 10 , Egger's test based on Stata 12.0 software was conducted to evaluate publication bias [22]. A sensitivity analysis was conducted to determine robustness of conclusions. P-value < 0.05 was considered statistically significant.

Results

Data collection and characteristics

A total of 4285 records were initially yielded from four electronic databases using a pre-designed search strategy. After removing duplicates, 2952 records remained. Twenty-one studies [13, 18, 19, 23-40] were ultimately included following a strict screening process. The comprehensive literature review and rigorous selection process are displayed in Fig. 1.

A total of 57241 patients were enrolled in 21 OBSs mainly originated from Asia (19/21), followed by South America (1/21) and Europe (1/21). Eight studies simultaneously analyzed OS and DFS, ten were with OS alone, and three were only related to DFS. The detailed patients' characteristics of demographic and clinicopathological aspects are shown in Table 1 and Supplementary Table 1. The quality of OBSs was assessed using NOS and assessment outcomes indicated that incorporated articles were of high quality (Supplementary Table 2).

Effect of STR on OS and DFS

A pooled analysis based on 18 studies including relevant OS data exhibited that STR was potentially related to a worse prognosis of ruptured HCC patients (HR, 1.65; 95% CI, 1.33-2.05) (Fig. 2). Consistent with the pooled result of OS, pooled DFS outcomes also illustrated that ruptured HCC patients had a poorer prognosis than non-ruptured HCC patients (HR, 1.42; 95% CI, 1.12-1.80) (Fig. 3).

Subgroup analysis

Subgroups analyses were implemented to explore the effect of various factors on the prognosis of ruptured and non-ruptured HCC patients. We categorized the studies into 3-year OS and 5-year OS groups based on recorded survival time. For subgroups of 5-year OS, non-ruptured HCC patients obtained greater OS than ruptured HCC patients, whereas no statistical difference was found in subgroups of 3-year OS. For subgroups of patients' age $\geq$ or < 60 years old, patients in China or other Asian countries, patients' AFP $\geq$ or < 400 ng/mL, patients with and without liver cirrhosis, and patients' microvascular invasion positive/negative, the analysis results all indicated that STR was associated with worse OS (Table 2). For patients with macrovascular invasion positive patients, STR had no adverse impact on ruptured HCC patients' OS compared to non-ruptured HCC patients (HR, 1.55; 95% CI, 0.99-2.42). However, in macrovascular invasion-negative patients, STR was a prognostic risk factor for HCC patients (HR, 1.67; 95% CI, 1.39-2.01) (Fig. 4).

Nine studies were included to explore the effect of age on DFS of HCC patients. The results demonstrated that in a subgroup of age < 60 years old, ruptured HCC patients' DFS was shorter than in the control group. Although no statistical difference was observed between the two groups' DFS regarding other Asian countries, non-ruptured HCC patients achieved better DFS than ruptured HCC patients in China. When patients' AFP concentration ≥ 400 ng/mL, STR is a potential risk factor for patients' DFS. However, in patients with AFP concentration < 400 ng/mL, STR was not correlated with HCC patients' DFS. For patients with liver cirrhosis, STR was linked to worse DFS. Similar poor outcomes were also demonstrated in microvascular invasion-negative patients, but in microvascular invasion-positive patients, no significant difference in DFS was identified between the two groups (Table 2). For DFS of patients, STR was not a prognostic risk factor in macrovascular invasion positive patients (HR, 1.23; 95% CI, 0.91-1.65), but it was a risk factor in macrovascular invasion negative patients (HR, 1.48; 95% CI, 1.06-2.05) (Fig. 5).

Sensitivity analysis and publication bias

After omitting the included articles in sequence, sensitivity analysis results confirmed the excellent stability of HR for OS. The quantificational Egger's test was employed to evaluate publication bias, and the outcomes revealed no potential publication bias among the included articles on HR for OS ($P > 0.05$). Additionally, another sensitivity analysis was performed to verify HR robustness for DFS, resulting in reliable results. No potential publication bias was observed for HR for DFS after Egger's test ($P > 0.05$).

Discussion

Most ruptured HCC patients were in advanced disease stage; among them, many patients exhibited extrahepatic metastasis, PVTT, and impaired liver function [14–17]. These tended to cause them to lose the opportunity of surgery and choose conservative treatment options. Therefore, the traditional concept that STR was a prognostic risk factor for HCC patients was mostly based on receiving non-surgical treatment [9, 12, 41, 42]. It is worth investigating whether STR remained a prognostic risk factor for those HCC patients undergoing liver resection. The overall findings from this meta-analysis implied that STR was a risk factor in long-term prognosis of HCC patients following hepatic resection, consistent with previous reports [19, 24, 32].

To thoroughly investigate the reasons of STR affecting long-term prognosis of HCC patients after hepatic resection, from previous literature, we inferred that potential reasons were correlated with gender, tumor size, virus status, hepatectomy style, and liver cirrhosis [13, 18, 24, 28, 37, 43–47]. STR was more frequently observed in male patients from reported studies [18, 24]. The literature revealed that HCC female patients exhibit a better survival rate and low recurrence rate than male patients [43]. Then, it was reported that ruptured HCC patients tended to have larger tumor size than non-ruptured HCC patients, and the total tumor volume is a vital prognostic predictor, and larger HCC was associated with a worse OS and DFS [37, 44]. From a nationwide survey (1160 ruptured HCC patients), Aoki et al. [13] found that hepatitis B virus (HBV)-infected patients have a higher STR incidence than hepatitis C virus (HCV)-infected patients. According to reports, long-term survival rates of HCC patients with hepatitis B surface antigen (HBsAg) positive was worse than that of HBsAg negative patients following surgery [45]. Additionally, staged hepatectomy followed TACE was a prevalent surgical way for ruptured HCC patients. Hanazaki et al. [46] found that preoperative TACE would significantly increase the risk of patients' postoperative recurrence, leading to unsatisfactory long-term prognosis. Besides, numerous studies revealed that ruptured HCC patients were often accompanied by liver cirrhosis, an independent prognostic risk factor affecting prognosis of HCC patients [28, 47]. For reduced liver reserve and tolerance, STR was undoubtedly a serious blow to the disease.

Due to high heterogeneity, the situations of ruptured HCC patients were complicated and diverse. We performed subgroup analyses of the prognosis of HCC patients. The analysis result of 5-year OS subgroup revealed that STR was a risk factor, but no statistical difference in survival was observed between the two groups in 3-year OS subgroup, possibly due to limited sample size (three included studies). In addition, long-term follow-up is required after hepatic resection to determine the difference in prognosis.

Our results indicated that STR was correlated with a poorer prognosis for both patients older or younger than 60 years old. There is still controversy regarding whether age affects tumor recurrence and long-term survival of HCC patients following hepatic resection. Numerous studies revealed that advanced age had no adverse effect on the prognosis of patients [48, 49]. Meanwhile, a previous study revealed that younger age possibly was a prognostic risk factor for HCC patients as they had more advanced tumor stage and stronger tumor aggressiveness than older HCC patients [50]. However, Xu et al. found that younger HCC patients tended to have a better survival outcome regardless of tumor aggressivity [51]. Moreover, our meta-analysis indicated that STR was linked to worse prognosis in China and other Asian countries. However, for other Asian countries, DFS result was not statistically different, possibly due to limited sample size. Besides, studies proved that HCV is the major etiology of HCC in Japan, whereas most Chinese HCC patients have an HBV background [52, 53]. The main HBV mechanisms contributing to HCC are that HBV-DNA integrates into the host genome and induces genomic instability and insertional mutagenesis of various cancer-related genes [54]. However, since HCV is an RNA virus without genes integrating into the host genome, direct cellular programming and indirect inflammatory response are possible mechanisms of inducing HCC [55]. Therefore, clinicopathological characteristics and prognoses of HCC caused by different viruses may differ.

We found that STR was a risk factor regardless of subgroups with low/high serum AFP concentrations. AFP, a specific tumor marker for primary HCC, is commonly employed for early screening and diagnosis of HCC; however, its specificity and sensitivity are relatively low [56]. Intriguingly, numerous investigations have discovered that several serum markers may assist in diagnosing AFP negative HCC patients [57, 58]. High AFP was linked to early recurrence and poor prognosis because it promoted vascular invasion and disease progression [59]. Subgroup analyses of liver cirrhosis revealed that STR was a prognostic risk factor in HCC patients with or without liver cirrhosis. Recent years have witnessed a surge in research on the risk factors for HBV-cirrhosis progressing to HCC. According to relevant literature, HBV status, antiviral drugs, and liver cirrhosis severity are potential prognostic factors [60–62].

Subgroup analysis was also used to assess the effect of microvascular invasion on prognosis. The outcomes indicated that for microvascular invasion-negative patients, ruptured HCC patients exhibited a worse prognosis than non-ruptured HCC patients. However, for microvascular invasion-positive patients, whether STR correlates with a worse prognosis remains controversial. Numerous studies have confirmed that microvascular invasion is an independent risk factor for prognosis of HCC patients undergoing hepatic resection and that occult metastases caused by microvascular invasion are a major cause of HCC recurrence following surgery [63, 64]. Furthermore, numerous investigations demonstrated a substantial correlation between the existence of microvascular invasion and large tumor size, high AFP concentration, and tumor localization in segment eight [65, 66]. Consequently, we speculated that, in addition to the harm caused by microvascular invasion, changes in associated clinicopathological indicators (tumor size, AFP, and tumor localization) might also cause controversies in the above results. Nowadays, it is challenging to detect microvascular invasion in preoperative imaging examination, and its diagnosis still requires validation using postoperative histopathological examination [18].

The most intriguing finding of subgroup analysis was that prognosis of ruptured HCC patients after hepatic resection was opposite depending on different macrovascular invasion status (positive/negative). STR was a significant prognostic risk factor for macrovascular invasion-negative patients; nevertheless, STR was not a prognostic risk factor in macrovascular invasion-positive patients. The possible explanation for this phenomenon is that adverse STR-related prognostic influence was overshadowed by the more harmful macrovascular invasion. In Barcelona Clinic Liver Cancer (BCLC) staging systems, macrovascular invasion HCC patients are classified as an advanced stage [67]. When macrovascular invasion is present, the prognosis is extremely poor, with a median survival time of 2.7 months if left untreated [68]. In addition, limited included studies in macrovascular positive-subgroup analyses (OS: 4 studies; DFS: 3 studies) might be a reason. PVTT is a prevalent type of HCC macrovascular invasion. There remain numerous controversies regarding the therapeutic options for HCC patients with PVTT. According to BCLC staging system of European and American countries, HCC patients with PVTT were classified as advanced (BCLC-C) stage, and sorafenib as a palliative treatment is recommended for these patients instead of surgery or other active methods [69]. However, unlike Western countries, Asia has numerous HCC patients and various treatment methods, and because each kind of HCC is unique, PVTT is not incompatible with hepatic resection [70]. Numerous doctors in Asian countries continue to use active methods like surgery to treat patients with well types and liver function, and the result revealed a favorable survival benefit than non-surgical treatment in reported literature [71, 72].

To the best of our knowledge, this is the first meta-analysis to assess the relationship between STR and prognosis of HCC patients following hepatic resection. Besides, various subgroup analyses were performed to investigate whether the risk effect of STR varied among various subgroups. However, this study has limitations. Firstly, the included studies were retrospective, resulting in potential risks like selection and information biases. Secondly, most populations

evaluated in this study were from Asia; therefore, the conclusion does not apply to Western areas with low HCC incidence. Thirdly, since the included studies were highly heterogeneous, relevant data like postoperative recurrence and complications are fully unavailable.

Conclusions

Our study demonstrated that STR was a risk factor for long-term prognosis of HCC patients after hepatectomy. This phenomenon remained consistent in most subgroups stratified by recorded survival time, age, country, AFP concentration, liver cirrhosis, and microvascular invasion. However, STR was not associated with a worse prognosis in macrovascular invasion patients.

List Of Abbreviations

HCC, hepatocellular carcinoma; STR, spontaneous tumor rupture; TACE, transcatheter arterial chemoembolization; PVTT, portal vein tumor thrombosis; OBSs, observational studies; OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; NOS, Newcastle-Ottawa scale; HBV, hepatitis B virus; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; BCLC, Barcelona clinic liver cancer.

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

Not applicable

Competing interests

The authors declare that they have no competing interests.

Funding

The study received no fund support.

Authors' contributions

Ping Chen designed the research process. Jiaxuan Xu and Lihu Gu searched the database for corresponding articles and drafted the meta-analysis. Yujing He and Yuexiu Si extracted useful information from the articles above. Binbin Xu used statistical software for analysis and polished this article. All authors had read and approved the manuscript and ensured that this was the case.

Acknowledgments

Not applicable

References

1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
2. Akinyemiju T, et al., *The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.* *JAMA Oncol.* 2017. **3**(12): p. 1683–1691.
3. Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. *Arch Surg.* 2006;141(2):191–8.
4. Hermann RE, David TE. Spontaneous rupture of the liver caused by hepatomas. *Surgery.* 1973;74(5):715–9.
5. Castells L, et al. Hemoperitoneum as a first manifestation of hepatocellular carcinoma in western patients with liver cirrhosis: effectiveness of emergency treatment with transcatheter arterial embolization. *Dig Dis Sci.* 2001;46(3):555–62.
6. Rossetto A, et al. Combined approach for spontaneous rupture of hepatocellular carcinoma. *World J Hepatol.* 2010;2(1):49–51.
7. Chen MF, et al. Clinical experience with hepatic resection for ruptured hepatocellular carcinoma. *Hepatogastroenterology.* 1995;42(2):166–8.
8. Chen WK, et al. Outcomes of emergency treatment in ruptured hepatocellular carcinoma in the ED. *Am J Emerg Med.* 2005;23(6):730–6.
9. Liu CL, et al. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. *J Clin Oncol.* 2001;19(17):3725–32.
10. Ong GB, Taw JL. Spontaneous rupture of hepatocellular carcinoma. *Br Med J.* 1972;4(5833):146–9.
11. Tan FL, et al. Factors affecting early mortality in spontaneous rupture of hepatocellular carcinoma. *ANZ J Surg.* 2006;76(6):448–52.

12. Kirikoshi H, et al. Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study. *BMC Gastroenterol.* 2009;9:29.
13. Aoki T, et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. *Ann Surg.* 2014;259(3):532–42.
14. Sonoda T, et al. Ruptured hepatocellular carcinoma evokes risk of implanted metastases. *J Surg Oncol.* 1989;41(3):183–6.
15. Miyamoto M, Sudo T, Kuyama T. Spontaneous rupture of hepatocellular carcinoma: a review of 172 Japanese cases. *Am J Gastroenterol.* 1991;86(1):67–71.
16. Xu HS, Yan JB. Conservative management of spontaneous ruptured hepatocellular carcinoma. *Am Surg.* 1994;60(8):629–33.
17. Vergara V, et al. Spontaneous rupture of hepatocellular carcinoma: surgical resection and long-term survival. *Eur J Surg Oncol.* 2000;26(8):770–2.
18. Chua DW, et al. Impact of spontaneous rupture on the survival outcomes after liver resection for hepatocellular carcinoma: A propensity matched analysis comparing ruptured versus non-ruptured tumors. *Eur J Surg Oncol.* 2019;45(9):1652–9.
19. Chan AC, et al. Prognostic influence of spontaneous tumor rupture on hepatocellular carcinoma after interval hepatectomy. *Surgery.* 2016;159(2):409–17.
20. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6(7):e1000097.
21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25(9):603–5.
22. Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. *Bmj.* 1997;315(7109):629–34.
23. Cheng CH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. *World J Surg Oncol.* 2011;9:114.
24. Fan ST, et al. Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. *Arch Surg.* 1999;134(10):1124–30.
25. Joliat GR, et al. Recurrence rate and overall survival of operated ruptured hepatocellular carcinomas. *Eur J Gastroenterol Hepatol.* 2018;30(7):792–6.
26. Kwon JH, et al. Surgical Outcomes of Spontaneously Ruptured Hepatocellular Carcinoma. *J Gastrointest Surg*; 2020.
27. Lee HS, et al. Impact of spontaneous hepatocellular carcinoma rupture on recurrence pattern and long-term surgical outcomes after partial hepatectomy. *World J Surg.* 2014;38(8):2070–8.
28. Li J, et al. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study. *World J Gastroenterol.* 2014;20(27):9121–7.
29. Miyoshi A, et al. Outcomes of patients with spontaneous rupture of hepatocellular carcinoma. *Hepatogastroenterology.* 2011;58(105):99–102.
30. Mizuno S, et al. Are the results of surgical treatment of hepatocellular carcinoma poor if the tumor has spontaneously ruptured? *Scand J Gastroenterol.* 2004;39(6):567–70.
31. Ruan S, et al. The role of hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma: a pilot study. *Ann Transl Med.* 2020;8(18):1132.
32. Ruiz E, et al. Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. *Heliyon.* 2016;2(1):e00052.
33. Tanaka S, et al. Surgical Outcomes for the Ruptured Hepatocellular Carcinoma: Multicenter Analysis with a Case-Controlled Study. *J Gastrointest Surg.* 2016;20(12):2021–34.
34. Uchiyama H, et al. Favorable Outcomes of Hepatectomy for Ruptured Hepatocellular Carcinoma: Retrospective Analysis of Primary R0-Hepatectomized Patients. *Anticancer Res.* 2016;36(1):379–85.
35. Xiao CZ, et al. A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. *Oncol Lett.* 2015;10(5):2787–94.
36. Yang T, et al. Partial hepatectomy for ruptured hepatocellular carcinoma. *Br J Surg.* 2013;100(8):1071–9.
37. Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. *Ann Surg Oncol.* 2003;10(9):1070–6.
38. Zhang XF, et al. Spontaneous tumor rupture and surgical prognosis of patients with hepatocellular carcinoma. *Scand J Gastroenterol.* 2012;47(8–9):968–74.
39. Zhao HC, et al. A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (> 5 cm) hepatocellular carcinoma. *HPB (Oxford).* 2016;18(11):943–9.
40. Zhu Q, et al., Conditional survival in patients with spontaneous tumor rupture of hepatocellular carcinoma after partial hepatectomy: a propensity score matching analysis. *HPB (Oxford).* 2019. 21(6): pp. 722–30.
41. Chearanai O, et al. Spontaneous rupture of primary hepatoma: report of 63 cases with particular reference to the pathogenesis and rationale treatment by hepatic artery ligation. *Cancer.* 1983;51(8):1532–6.
42. Hirai K, et al. Transcatheter arterial embolization for spontaneous rupture of hepatocellular carcinoma. *Am J Gastroenterol.* 1986;81(4):275–9.
43. Villa E, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. *Hepatology.* 2000;32(2):233–8.
44. Goh BK, et al. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system. *J Surg Oncol.* 2016;113(1):89–93.
45. Wu CC, et al. Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. *Br J Surg.* 1999;86(11):1391–6.

46. Hanazaki K, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. *J Am Coll Surg*. 2000;191(4):381–8.
47. Taura K, et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. *Surgery*. 2007;142(5):685–94.
48. Kim JM, et al. Hepatectomy is a reasonable option for older patients with hepatocellular carcinoma. *Am J Surg*. 2015;209(2):391–7.
49. Tsujita E, et al. Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. *Surgery*. 2010;147(5):696–703.
50. Kim JH, et al. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. *J Gastroenterol Hepatol*. 2006;21(3):588–94.
51. Xu XS, et al. Survival Analysis of Hepatocellular Carcinoma: A Comparison Between Young Patients and Aged Patients. *Chin Med J (Engl)*. 2015;128(13):1793–800.
52. Ukawa S, et al. Characteristics of patients with liver cancer in the BioBank Japan project. *J Epidemiol*. 2017;27(3s):S43-s48.
53. Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. *Best Pract Res Clin Gastroenterol*. 2015;29(6):919–28.
54. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. *J Hepatol*. 2016;64(1 Suppl):S84-s101.
55. Dash S, et al. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. *J Hepatocell Carcinoma*. 2020;7:45–76.
56. Tangkijvanich P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. *J Clin Gastroenterol*. 2000;31(4):302–8.
57. Shen Q, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. *Lancet Oncol*. 2012;13(8):817–26.
58. Capurro M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. *Gastroenterology*. 2003;125(1):89–97.
59. Peng SY, et al. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. *Int J Cancer*. 2004;112(1):44–50.
60. Chien J, et al. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. *J Gastroenterol Hepatol*. 2016;31(12):1971–7.
61. Bonino F, et al. Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. *J Viral Hepat*. 1997;4(Suppl 2):79–82.
62. Shim JJ, et al. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. *Scand J Gastroenterol*. 2017;52(9):1029–36.
63. Rodríguez-Perálvarez M, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. *Ann Surg Oncol*. 2013;20(1):325–39.
64. Imamura H, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. *J Hepatol*. 2003;38(2):200–7.
65. McHugh PP, et al. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. *HPB (Oxford)*. 2010;12(1):56–61.
66. Al-Azzawi Y, et al., *Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation*. *J Cancer Epidemiol*, 2019. **2019**: p. 8534372.
67. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis*. 1999;19(3):329–38.
68. Llovet JM, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology*. 1999;29(1):62–7.
69. Forner A, et al. Current strategy for staging and treatment: the BCLC update and future prospects. *Semin Liver Dis*. 2010;30(1):61–74.
70. Kudo M, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. *Liver Cancer*. 2014;3(3–4):458–68.
71. Kokudo T, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. *J Hepatol*. 2016;65(5):938–43.
72. Zhang ZY, et al. Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis. *Medicine*. 2019;98(50):e18362.

Tables

Table 1. Characteristics of all the studies included in the meta-analysis.

Author	Year	Country	Number of patients		AFP(ng/ml)		Liver cirrhosis(number)		Microvascular invasion(number)		Macrovascular invasion(number)	
			Rupture	Non-rupture	Rupture	Non-rupture	Rupture	Non-rupture	Rupture	Non-rupture	Rupture	Non-rupture
Aoki	2014	Japan	1160	48548	510 cases $\geq$ 400 504 cases<400	9279 cases $\geq$ 400 36431 cases<400	579	26473	NA	NA	352	5373
Chan	2016	China	84	1254	472	91	43	750	52	583	9	102
Cheng	2011	China	53	826	66.8		507		104		188	
Chua	2019	Singapore	49	98	NA	NA	19	32	27	47	7	11
Fan	1999	China	211		NA	NA	98		NA	NA	21	
Joliat	2018	Switzerland	14	126	23	18	11	81	NA	NA	NA	NA
Kwon	2020	Korea	85	186	12151	14908	NA	NA	29	58	7	13
Lee	2014	Korea	18	37	NA	NA	11	21	12	26	8	13
Li	2014	China	89	171	138.5	73.8	73	99	0	0	NA	NA
Miyoshi	2011	Japan	10	295	3 cases $\geq$ 1000 7 cases<1000	53 cases $\geq$ 1000 242 cases<1000	NA	NA	NA	NA	6	81
Mizuno	2004	Japan	6	15	3 cases>400 3 cases<400	5 cases>400 10 cases<400	NA	NA	NA	NA	5	6
Ruan	2020	China	57	57	22	20	28	NA	23	21	NA	NA
Ruiz	2016	Peru	253		2651		39		64		29	
Tanaka	2016	Japan	42	42	78.8	49.5	13	14	NA	NA	2	3
Uchiyama	2006	Japan	27	1004	168 cases $\geq$ 400 836 cases<400		NA	NA	NA	NA	40	
Xiao	2015	China	53	181	141 cases $\geq$ 400 93 cases<400		196		144		234	
Yang	2013	China	143	1090	85 cases $\geq$ 400 58 cases<400	420 cases $\geq$ 400 670 cases<400	NA	NA	97	668	36	172
Yeh	2003	China	35	175	100 cases $\geq$ 400 110 cases<400		63		NA	NA	116	
Zhang	2012	China	41	446	5788.9	3947.1	24	285	NA	NA	1	48
Zhao	2016	China	12	70	35 cases $\geq$ 400 47 cases<400		65		19		0	0
Zhu	2019	China	89	89	57 cases $\geq$ 400 32 cases<400	53 cases $\geq$ 400 36 cases<400	76	80	65	60	50	43

AFP, a-fetoprotein; NA, not available.

Table 2. Subgroup analysis of the hepatocellular carcinoma (HCC) rupture on the prognosis of patients with HCC.

	No. of studies	HR	95%CI	Heterogeneity (I ²) (%)
Overall survival (OS)				
3-year OS	3	1.87	0.80-4.39	86.4
5-year OS	15	1.68	1.46-1.94	54.8
Age≥60 years	5	1.78	1.19-2.65	68.3
Age<60 years	11	1.66	1.47-1.88	0
China	9	1.68	1.47-1.92	0
Non-Chinese Asian countries	7	1.50	1.00-2.26	96.2
AFP≥400ng/ml	6	1.74	1.45-2.09	0
AFP<400ng/ml	8	1.58	1.09-2.28	95.3
Liver cirrhosis	7	2.09	2.02-2.17	0
Non-liver cirrhosis	5	1.56	1.23-1.98	26.2
Microvascular invasion positive	4	1.55	1.25-1.91	30.4
Microvascular invasion negative	5	1.74	1.40-2.17	0
Disease-free survival (DFS)				
Age<60	9	1.53	1.24-1.88	31.4
China	7	1.50	1.18-1.90	36.7
Non-Chinese Asian countries	4	1.22	0.67-2.24	74.3
AFP≥400ng/ml	4	1.42	1.07-1.90	49.9
AFP<400ng/ml	4	1.35	0.93-1.97	3.4
Liver cirrhosis	7	1.52	1.15-2.01	38.5
Microvascular invasion positive	4	1.11	0.74-1.65	70.6
Microvascular invasion negative	5	1.64	1.30-2.06	3.6

AFP, alpha fetoprotein; HR, hazard ratio; CI, confidence interval.

Figures

Figure 1

A schematic flow for selecting the articles included in this meta-analysis.

Figure 2

Forest plot of OS of ruptured hepatocellular carcinoma (HCC) patients after hepatectomy (P<0.001).

Figure 3

Forest plot of DFS of ruptured hepatocellular carcinoma (HCC) patients following hepatectomy (P=0.004).

Figure 4

Forest plot of OS of ruptured hepatocellular carcinoma (HCC) patients with macrovascular invasion after hepatectomy (a, macrovascular invasion positive, P=0.055; b, macrovascular invasion negative, P<0.001).

Figure 5

Forest plot of DFS of ruptured hepatocellular carcinoma (HCC) patients with macrovascular invasion after hepatectomy (a, macrovascular invasion positive, P=0.170; b, macrovascular invasion negative, P=0.021).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTable1.docx](#)
- [SupplementaryTable2.docx](#)